Literature DB >> 7831630

Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection.

P J Cook1, J M Andrews, J Woodcock, R Wise, D Honeybourne.   

Abstract

BACKGROUND: The efficacy of an antibiotic is usually predicted from serum levels and MIC90 values for likely pathogens, but in the lung tissue concentrations may be more informative. This study compares concentrations of amoxycillin and clavulanate in serum, epithelial lining fluid (ELF), alveolar macrophages, and bronchial mucosa in 15 adults.
METHODS: Amoxycillin 500 mg and clavulanic acid 250 mg were given 1-2 hours before diagnostic bronchoscopy for haemoptysis or radiological abnormality. Mucosal biopsy samples were taken from macroscopically normal sites, alveolar macrophages harvested by lavage, and ELF volume derived from urea concentrations in bronchial lavage fluid and blood. Amoxycillin was assayed by inhibition of growth of Micrococcus lutea, and clavulanate (in serum, ELF, and bronchial mucosa) by inhibition of growth of Klebsiella pneumoniae; in macrophages clavulanate was measured by high performance liquid chromatography.
RESULTS: The median concentrations in serum were 6.90 mg/l for amoxycillin and 5.25 mg/l for clavulanate. The median bronchial mucosal concentration of amoxycillin was 2.99 mg/l and of clavulanate was 1.65 mg/l; the median concentrations in ELF were 0.89 and 0.96 mg/l, and in macrophages 0 and 0.76 mg/l, respectively. In macrophages amoxycillin levels were undetectable in 10 of 14 subjects (71%); by contrast, only 6 of 14 subjects (43%) had no detectable clavulanate.
CONCLUSIONS: Clavulanate levels exceeded quoted MIC90 values (around 0.25 mg/l) for Legionella pneumophila both in ELF and in macrophages. Amoxycillin-clavulanate may therefore have a clinical role in infections with Legionella pneumophila.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7831630      PMCID: PMC475276          DOI: 10.1136/thx.49.11.1134

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

1.  Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group.

Authors:  J D Wenger; A W Hightower; R R Facklam; S Gaventa; C V Broome
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.

Authors:  D Legnani; V M Lombardo; G G Negretto; G Beghi; O Caratozzolo
Journal:  J Hosp Infect       Date:  1992-11       Impact factor: 3.926

3.  Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.

Authors:  D R Baldwin; J M Andrews; J P Ashby; R Wise; D Honeybourne
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

4.  Amoxycillin/clavulanic acid levels in lower respiratory secretions.

Authors:  I M Gould; J S Legge; T M Reid
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

5.  Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections.

Authors:  T A Stamey; W R Fair; M M Timothy; M A Millar; G Mihara; Y C Lowery
Journal:  N Engl J Med       Date:  1974-11-28       Impact factor: 91.245

6.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

7.  beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis.

Authors:  Y Zhang; V A Steingrube; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1992-03

8.  Prevention of pyelonephritis due to Escherichia coli in rats with gentamicin stored in kidney tissue.

Authors:  M P Glauser; J M Lyons; A I Braude
Journal:  J Infect Dis       Date:  1979-02       Impact factor: 5.226

9.  Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections.

Authors:  C Brambilla; S Kastanakis; S Knight; K Cunningham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

10.  Bactericidal effects of amoxycillin/clavulanic acid against Legionella pneumophila.

Authors:  D H Stokes; B Slocombe; R Sutherland
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

View more
  11 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 2.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 4.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

5.  Co-amoxiclav levels in bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; R Wise
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

6.  Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Anasuya Patel; Rajesh Chavan; Ravindra Yeole; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Robin D Isaacs; John P O'Donnell; Emily Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

8.  Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Vipul Gupta; Amanda Ek; Praveen Srivastava; Angela Talley; Jon Bruss
Journal:  Antimicrob Agents Chemother       Date:  2022-06-28       Impact factor: 5.938

9.  Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.

Authors:  Matthew L Rizk; Elizabeth G Rhee; Patricia A Jumes; Mark H Gotfried; Tian Zhao; Eric Mangin; Sheng Bi; Cynthia M Chavez-Eng; Zufei Zhang; Joan R Butterton
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

10.  Conference report on public health and clinical guidelines for anthrax.

Authors:  Eric Jacob Stern; Kristin Broome Uhde; Sean Vincent Shadomy; Nancy Messonnier
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.